TY - JOUR
T1 - US pharmaceutical innovation in an international context
AU - Keyhani, Salomeh
AU - Wang, Steven
AU - Hebert, Paul
AU - Carpenter, Daniel
AU - Anderson, Gerard
PY - 2010/6/1
Y1 - 2010/6/1
N2 - Objectives. We explored whether the United States, which does not regulate pharmaceutical prices, is responsible for the development of a disproportionate share of the new molecular entities (NMEs; a drug that does not contain an active moiety previously approved by the Food and Drug Administration produced worldwide. Methods. We collected data on NMEs approved between 1992 and 2004 and assigned each NME to an inventor country. We examined the relation between the proportion of total NMEs developed in each country and the proportion of total prescription drug spending and gross domestic product {GDP) of each country represented. Results. The United States accounted for 42% of prescription drug spending and 40% of the total GDP among innovator countries and was responsible for the development of 43.7% of the NMEs. The United Kingdom, Switzerland, and a few other countries innovated proportionally more than their contribution to GDP or prescription drug spending, whereas Japan, South Korea, and a few other countries innovated less. Conclusions. Higher prescription drug spending in the United States does not disproportionately privilege domestic innovation, and many countries with drug price regulation were significant contributors to pharmaceutical innovation.
AB - Objectives. We explored whether the United States, which does not regulate pharmaceutical prices, is responsible for the development of a disproportionate share of the new molecular entities (NMEs; a drug that does not contain an active moiety previously approved by the Food and Drug Administration produced worldwide. Methods. We collected data on NMEs approved between 1992 and 2004 and assigned each NME to an inventor country. We examined the relation between the proportion of total NMEs developed in each country and the proportion of total prescription drug spending and gross domestic product {GDP) of each country represented. Results. The United States accounted for 42% of prescription drug spending and 40% of the total GDP among innovator countries and was responsible for the development of 43.7% of the NMEs. The United Kingdom, Switzerland, and a few other countries innovated proportionally more than their contribution to GDP or prescription drug spending, whereas Japan, South Korea, and a few other countries innovated less. Conclusions. Higher prescription drug spending in the United States does not disproportionately privilege domestic innovation, and many countries with drug price regulation were significant contributors to pharmaceutical innovation.
UR - http://www.scopus.com/inward/record.url?scp=77952282664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952282664&partnerID=8YFLogxK
U2 - 10.2105/AJPH.2009.178491
DO - 10.2105/AJPH.2009.178491
M3 - Article
C2 - 20403883
AN - SCOPUS:77952282664
SN - 0090-0036
VL - 100
SP - 1075
EP - 1080
JO - American Journal of Public Health
JF - American Journal of Public Health
IS - 6
ER -